Manx Healthcare Ltd.

Manx Healthcare Limited is a pharmaceutical company focused on developing and supplying high-quality generic and Over-The-Counter (OTC) products to healthcare providers across multiple therapeutic areas. Manx Healthcare Limited, founded in 1996 in Warwick, UK, specializes in pharmaceuticals. The company has maintained its focus on generic and OTC products throughout its history. In April 2025, it entered an Add-on funding round, raising GBP 19.

7 million from Tillomed Laboratories Ltd, marking a significant step in its financial growth. Manx Healthcare specializes in the development, manufacturing, and supply of high-quality pharmaceuticals, focusing on both Generic and Over-The-Counter (OTC) products. Their diverse portfolio includes a range of generic medications catering to therapeutic areas such as pain relief, dental care, and gut health, alongside niche products for specific medical needs. With over 20 years of operation, the company has established a robust client base, including pharmacies, hospitals, and healthcare providers across the UK and internationally, ensuring access to effective pharmaceutical solutions.

Manx Healthcare's revenue model is structured around business-to-business (B2B) transactions, targeting wholesalers and retailers in the pharmaceutical industry. The company engages in direct sales to pharmacies and healthcare providers, facilitating the distribution of its extensive range of products through bulk orders, ensuring clients have access to essential medications. Pricing strategies reflect the quality of their flagship products, fostering long-term partnerships with clients and supporting a stable revenue stream. In April 2025, Tillomed Pharma GmbH announced its intention to acquire Manx Healthcare Limited for GBP 19.

7 million, with an upfront payment of approximately GBP 6. 2 million and milestone payments over the next 18 months. This acquisition aims to expand Tillomed Pharma GmbH's market reach and leverage Manx Healthcare's product offerings. The company is also looking to launch new products designed to address unmet medical needs while targeting expansion into international markets, aiming to enhance its global footprint significantly.